CAPS-1 Activators
CAPS-1 activators constitute a group of chemicals that target various cellular processes to potentiate the functional activity of CAPS-1, a protein integral to vesicle trafficking and neurotransmitter release. Compounds such as Forskolin harness the adenylyl cyclase pathway to elevate intracellular cAMP, which in turn activates PKA. This kinase is known to phosphorylate proteins that aid the priming and docking of vesicles, a process that CAPS-1 is directly involved in, thus amplifying its activity. Similarly, Phorbol 12-myristate 13-acetate (PMA) engages protein kinase C (PKC), which may phosphorylate proteins that enhance CAPS-1's membrane association, a crucial step for vesicle docking. Epinephrine, via adrenergic receptors, can also raise cAMP levels, potentially facilitating CAPS-1 activity through PKA-mediated phosphorylation, essential for synaptic vesicle exocytosis. Brefeldin A, though its action is indirect, disrupts the Golgi apparatus, potentially leading to alterations in protein redistribution that could compensate by upregulating CAPS-1 activity in vesicle formation and release.
Furthermore, Nifedipine and Nicotine both act to modulate intracellular calcium concentrations, which is a key regulator of CAPS-1-mediated vesicular release. Nifedipine does so through its action as a calcium channel blocker, whereas Nicotine activates nicotinic acetylcholine receptors, promoting calcium influx. Clostridium botulinum toxin, albeit through a pathogenic mechanism, cleaves SNARE proteins, which could trigger homeostatic responses that upregulate CAPS-1 activity to maintain neurotransmission. Tetraethylammonium (TEA) blocks potassium channels, augmenting depolarization-induced calcium influx, thus indirectly promoting CAPS-1's role in vesicle fusion. Methylxanthines like Caffeine inhibit phosphodiesterases, leading to increased cAMP and enhanced CAPS-1 activity via PKA signaling. Veratridine activates voltage-gated sodium channels, intensifying depolarization, and potentially increasing CAPS-1 activity by promoting calcium entry. Lastly, Ryanodine affects ryanodine receptors to release calcium from intracellular stores, supporting CAPS-1 in calcium-dependent exocytosis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, increasing intracellular cAMP levels. Elevated cAMP activates PKA, which can then phosphorylate substrate proteins that regulate vesicle exocytosis, subsequently enhancing the functional activity of CAPS-1 which is involved in the regulation of vesicle docking and priming. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which phosphorylates target proteins that influence vesicular trafficking. PKC activation may enhance CAPS-1 activity by promoting its association with the membrane where it facilitates vesicle docking. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds to adrenergic receptors, leading to the activation of cAMP-dependent pathways. The increase in cAMP may enhance CAPS-1 activity by PKA-mediated phosphorylation events, which are necessary for synaptic vesicle exocytosis. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi apparatus, which can lead to the redistribution of proteins that regulate vesicle formation, indirectly enhancing CAPS-1 function in the vesicle release process. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine is a calcium channel blocker that indirectly increases intracellular calcium concentration in certain conditions, which may enhance CAPS-1 activity by promoting calcium-dependent exocytosis of vesicles. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Methylxanthines inhibit phosphodiesterases, leading to an increase in cAMP levels, which can enhance CAPS-1 activity by stimulating PKA and subsequent phosphorylation of proteins involved in vesicle exocytosis. | ||||||
Veratridine | 71-62-5 | sc-201075B sc-201075 sc-201075C sc-201075A | 5 mg 10 mg 25 mg 50 mg | $82.00 $104.00 $201.00 $379.00 | 3 | |
Veratridine is a voltage-gated sodium channel activator that enhances depolarization and can indirectly increase CAPS-1 activity by promoting more frequent or sustained calcium entry through voltage-gated calcium channels. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $223.00 $799.00 | 19 | |
Ryanodine modulates ryanodine receptors which release calcium from intracellular stores. The elevation of intracellular calcium can enhance CAPS-1 activity, thereby facilitating the calcium-dependent exocytosis process. | ||||||